mRNA Based Vaccine Development

mRNA Based Vaccine Development

Ziphius Therapeutics


Risk communication & Community Engagement


Belgium, Europe


ZIPHIUS Therapeutics announced that they have prioritized their resources to intensify the development of ZIP-1642, a vaccine against the novel coronavirus. Ziphius Therapeutics is therefore interacting with researchers at Ghent University who recently succeeded to produce an mRNA vaccine against Zika virus. This mRNA platform could also be applicable for the development of a COVID-19 vaccine.